Categories: Health

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

 | Source: ZENTALIS PHARMACEUTICALS

SAN DIEGO, Oct. 01, 2025 (GLOBE NEWSWIRE) — Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on October 1, 2025, the Compensation Committee of Zentalis’ Board of Directors granted the following equity awards: non-qualified stock options to purchase an aggregate of 400,000 shares of the Company’s common stock to James B. Bucher, JD, who joined the Company as Chief Legal Officer and Corporate Secretary, and non-qualified stock options to purchase an aggregate of 15,000 shares of the Company’s common stock to two (2) additional newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an inducement material to each such individual’s entering into employment with Zentalis, pursuant to Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $1.54 per share, which is equal to the closing price of Zentalis’ common stock on The Nasdaq Global Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter.

Vesting of the stock options is subject to the employee’s continued service to Zentalis on each vesting date.

About Zentalis Pharmaceuticals
Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC. Zentalis has operations in San Diego.

For more information, please visit www.zentalis.com. Follow Zentalis on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.

Contacts:
Aron Feingold – VP, IR & Corp Comms
ir@zentalis.com

GlobeNews Wire

Recent Posts

New Imprivata Report Finds that Australian Hospitals Save More Than $1.2 Million AUD Annually with Shared-Use Mobile Devices, but Strategic Gaps Still Pose Security and Operational Risk

MELBOURNE, Australia, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Imprivata, a leading provider of access management solutions…

2 hours ago

New York Explorers Club Hosts Global Book Launch of Hope for Life on Our Planet: Inspiration for Seven Generations for 80th UNGA and Climate Week

Actor Michael Douglas Speech Elevates Hope As Pathway for Global Leadership Dame Jane Goodall and…

2 hours ago

EVEREADY ANNOUNCES HARRY KANE AS GLOBAL BRAND AMBASSADOR

Partnership with international football star and family man is part of broader international marketing effort…

2 hours ago

IOC President welcomes NOC of Palestine to Olympic House

01 October 2025 - IOC President Kirsty Coventry welcomed a delegation of the National Olympic Committee (NOC) of…

3 hours ago

Lamborghini Polo Storico and the Diablo star at the Concorso di Varignana and the Festival Car in Turin

The last Diablo ever produced was the star of the Festival Car in Moncalieri and…

5 hours ago

Kia America Posts Best Quarter and Highest YeartoDate Sales in Company History

Record third quarter pushes Kia’s total year-to-date sales up 9 percent over 2024Double-digit dealer sales…

5 hours ago